Oxprenolol

Summary

Oxprenolol (CHEMBL546) is an approved small molecule (ATC C07AA02); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C07AA02
• Indications: 1 condition
• Chemistry: 265.35 Da · C15H23NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL546
Name	Oxprenolol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4631
ATC	C07AA02
Molecular formula	C15H23NO3
Molecular weight	265.35
InChIKey	CEMAWMOMDPGJMB-UHFFFAOYSA-N

SMILES: CC(C)NCC(COC1=CC=CC=C1OCC=C)O

IUPAC name: 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol

Also known as: Oxprenolol, oxprenolol, SID11112583, OXPRENOLOL

Parent form; salt/anhydrous children: CHEMBL1200745, CHEMBL3245937

Patent coverage: 3,685 distinct patent families (14,825 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 14,823 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Prelamin-A/C, Beta-2 adrenergic receptor, Beta-1 adrenergic receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, 5-hydroxytryptamine receptor 1A, Cytochrome P450 2D6, Cytochrome P450 1A2.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRB2	8.33	AC50	4.7	nM	CHEMBL_ACT_25123030
ADRB1	8.18	AC50	6.6	nM	CHEMBL_ACT_25121968
P19327	7.03	Ki	93.33	nM	CHEMBL_ACT_842600
LMNA	6.9	Potency	125.9	nM	CHEMBL_ACT_3626883
HTR1A	6.15	AC50	710.4	nM	CHEMBL_ACT_25164568
ADRA1A	5.52	AC50	2998	nM	CHEMBL_ACT_25138054
CYP1A2	5.3	AC50	5012	nM	CHEMBL_ACT_6055737
CYP2D6	5.1	Potency	7943	nM	CHEMBL_ACT_4969900
CYP2D6	5.1	AC50	7943	nM	CHEMBL_ACT_6062918
ADRA1A	5.08	AC50	8300	nM	CHEMBL_ACT_25218206

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).